REAL-WORLD CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH METASTATIC DUCTAL ADENOCARCINOMA (MPDAC) TREATED WITH LIPOSOMAL IRINOTECAN-BASED REGIMENS BY RACE

被引：0

作者：

Kim, G. P. ^{[1
]}

Cockrum, P. ^{[2
]}

Lamarre, N. ^{[3
]}

Surinach, A. ^{[3
]}

机构：

[1] George Washington Univ, Washington, DC USA

[2] Ipsen, Cambridge, MA USA

[3] Genesis Res, Hoboken, NJ USA

来源：

VALUE IN HEALTH | 2021年 / 24卷

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCN27

引用

页码：S23 / S23

页数：1

共 50 条

[1] REAL-WORLD IMPACT OF PRIOR SURGERY ON OUTCOMES OF PATIENTS WITH METASTATIC DUCTAL ADENOCARCINOMA (MPDAC) TREATED WITH LIPOSOMAL IRINOTECAN-BASED REGIMENS
George, B.
Cockrum, P.
Lamarre, N.
Surinach, A.
VALUE IN HEALTH, 2021, 24 : S21 - S21
[2] Real-world clinical outcomes of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens: Impact of prior irinotecan (IRI) exposure
Yu, Kenneth H.
Cockrum, Paul
Surinach, Andy
Lamarre, Neil
Wang, Shu
O'Reilly, Eileen Mary
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[3] Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States
Kim, G.
Cockrum, P.
Surinach, A.
Wang, S.
Lamarre, N.
ANNALS OF ONCOLOGY, 2021, 32 : S1092 - S1093
[4] Real-world treatment discontinuation patterns among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States
Kim, G.
Surinach, A.
Wang, S.
Lamarre, N.
Cockrum, P.
ANNALS OF ONCOLOGY, 2021, 32 : S1107 - S1108
[5] Real-world use of liposomal irinotecan-based regimens among patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) in the United States (US).
Kim, George P.
Cockrum, Paul
Surinach, Andy
Koeller, Jim M.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[6] Understanding extended duration of therapy (DOT) among patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens
Mokrzecky, Cheryl
Cockrum, Paul
Surinach, Andy
Becerra, Carlos Roberto
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[7] Trends in real-world clinical outcomes among patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) treated with liposomal irinotecan based regimens in the United States (US).
Koeller, Jim M.
Cockrum, Paul
Belanger, Bruce
Corvino, Frank A.
Surinach, Andy
Kim, George P.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Real-world dosing, management, and clinical outcomes of patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC) treated with liposomal irinotecan.
Abushahin, Laith, I
Cockrum, Paul
Surinach, Andy
Belanger, Bruce
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Multivariable analysis of real-world clinical outcomes associated with dose reductions (DRs) for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan
Abushahin, L.
Cockrum, P.
Surinach, A.
Belanger, B.
ANNALS OF ONCOLOGY, 2020, 31 : S943 - S944
[10] Comparing real-world evidence among patients with metastatic pancreatic ductal adenocarcinoma treated with liposomal irinotecan
Koeller, Jim
Surinach, Andy
Arikian, Steven R.
Zivkovic, Marko
Janeczko, Patrick
Cockrum, Paul
Kim, George
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12

← 1 2 3 4 5 →